Abstract

Peptide-based small molecule drug conjugates for targeted tumor therapy are currently in the focus of intensive research. Anthracyclines, like daunomycin, are commonly used anticancer drug molecules and are also often applied in peptide-drug conjugates. However, lability of the O-glycosidic bond during electrospray ionization mass spectrometric analysis hinders the analytical characterization of the constructs. “Overprotonation” can occur if daunomycin is linked to positively charged peptide carriers, like tuftsin derivatives. In these molecules, the high number of positive charges enhances the in-source fragmentation significantly, leading to complex mass spectra composed of mainly fragment ions. Therefore, we investigated different novel tuftsin-daunomycin conjugates to find an appropriate condition for mass spectrometric detection. Our results showed that shifting the charge states to lower charges helped to keep ions intact. In this way, a clear spectrum could be obtained containing intact protonated molecules only. Shifting of the protonation states to lower charges could be achieved with the use of appropriate neutral volatile buffers and with tuning the ion source parameters.

Highlights

  • Daunomycin is a commonly used drug for cancer therapy, which is applied, especially in leukemia [1]

  • All peptides were synthesized by solid-phase methodology using the Fmoc/tBu strategy

  • All peptides were synthesized by solid-phase was methodology using the

Read more

Summary

Introduction

Daunomycin is a commonly used drug for cancer therapy, which is applied, especially in leukemia [1]. It belongs to the family of anthracycline antibiotics that can bind to the DNA in the nucleus and can inhibit the topoisomerase IIα enzyme [1,2]. To overcome clinical drawbacks, such as the lack of selectivity, the fast elimination from the blood circulation, as well as toxicity, peptide-based bioconjugates containing daunomycin for targeted therapy have been in the focus of intensive interest since years [3,4,5]. The drug moiety, usually, is attached to a targeting peptide, which can bind to a receptor overexpressed in tumor cells, and the selective binding results in a specific antitumor effect [6]

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.